That dependence has grown dramatically over the years
The company has not yet chosen a replacement
15, 30 June 2025, 100188, Pich, Marie-Eve, Andr Tchernof, and Jean-Pierre Desprs
Semaglutide authorised as Ozempic is not currently recognised by regulators as causing specific vulvovaginal adverse reactions such as vaginal dryness, vulvovaginal candidiasis, altered discharge, dyspareunia, vaginal atrophy, or vaginal mucosal injury
Furthermore, these results were verified in three RCTs (ALVEOLI, FACTT, and SAILS trials), 122,123,124 with a significant interaction between the three subphenotypes and treatment strategies in the ALVEOLI and FACTT trials
Read ERIC President & CEO James Gelfands latest oped in the Washington Examiner